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ABSTRACT 
The Myc proto-oncogene, is a highly disordered (lack of structure formation) transcription 
factor (TF), which can bind to its partner proteins and regulate different biological functions 
of the cells including proliferation, cell cycle, differentiation and apoptosis. In general, Myc 
deregulation is a major prime force in human tumors, which contributes to their uncontrolled 
cell proliferation, metastasis and tumor cell immortalizations. In particular, Myc expression 
influences the transcriptional profile of cells by promoting RNA Polymerase II gene 
transcription to produce mRNA, as well as the transcription of the rRNA and tRNA genes 
transcribed by RNA Polymerase I and III, respectively. Thus, controlling expression of 
ribosome components, required for protein synthesis, appears to be an important role of Myc 
in normal and cancer cells.  
In this thesis, I have studied phylogenetic and molecular evolution of the Myc family 
proteins, for the first time exploiting their protein order/disorder properties and the extent of 
their conservation through the Metazoan and beyond. We systematically analyzed the 
predicted protein disorder profile of Myc family proteins using a range of different 
algorithms. Therefore, we showed that all Myc proteins are structurally disordered TFs and 
most of the interaction domains of c-Myc are within disordered regions. Moreover, Using 
Intrinsically Disorder Protein (IDP) profiles we established a new way to evaluate the 
evolution of TFs based on their disorder profile. Use of IDR predictions instead of protein 
sequences produced a better-supported phylogenetic tree of Myc proteins, including large 
clades containing c-Myc, MycN, MycL and dMyc proteins. In addition, we analyzed the 
effect of Burkitt’s lymphoma (BL) mutations on the disorder profile and suggested that these 
adaptive BL-Associated Mutations (BL-AM) could change the local conformation of c-Myc 
and thereby its functions.  
Next, we studied Myc in the nucleolus, an adaptive context that has scarcely been studied, 
and its involvement in spatial chromatin domain organization of the rRNA genes. 
Accordingly, we found that Myc activation caused altered spatial organization of the 
mammalian rDNA by tethering the rDNA to the nucleolar scaffold/matrix via non-transcribed 
intergenic spacer sequences of the rDNA. In addition, in rat fibroblast cell lines we found that 
matrix associated rRNA genes are hypo-methylated on DNA sites in their upstream core 
promoter regions (CpG site at position -145).  
Finally, I characterized lymphoma-associated gene expression induced by wild type Myc and 
how it is adapted in response to BL-AM (T58A and T58I). For this purpose, I established a 
cell system, consisting of low passage primary B-cells transduced with lentivirus expression 
constructs, in which wild type or BL-AM Myc could be induced to varying degrees by 
doxycycline in order to progressively promote a lymphoma-like phenotype. The transduced 
cells also constitutively over-expressed the BMI1 and BCLXL proteins to inhibit apoptosis. 
Progressive increase in Myc expression was associated with a progressive increase in cell 
proliferation, size and proportion of cells in S-phase for both wild type Myc and BL-AM, 
  
albeit with some differences between the different Myc proteins. RNA-Seq was used to 
measure cellular transcripts at seven different doxycycline concentrations for cells expressing 
wild type and BL-AM Myc. Generalized linear models (as implemented in the MaSigPro 
package (v3.3)) were then used to identify differentially regulated genes (DEG) with regard 
to Myc level and/ or mutant status. Thus, we found 4443 DEG common to all three-cell 
system as well as 543 DEG deregulated only in T58A and T58I cells. On the other hand, the 
results show DEG common between wild type and T58A (n=553) as well as between wild 
type and T58I (n=1062). Further analysis, identified 15 gene clusters with different patterns 
of differential gene expression and these genes were enriched in generally distinct sets of 
gene ontology terms, indicating little functional overlap between clusters. The data identify 
gene sets induced by Myc as the cells convert to lymphoma-like cells as well as gene sets 
where one or both BL-AM augment changes induced by wild type Myc. 
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1 INTRODUCTION TO MYC AND CANCER 
1.1 MYC  
Myc (v-myc) was first identified in bird myelocytomatosis (a leukemic disorder) caused by 
integration of avian oncogenic retroviruses (MC29)[1]. Thereafter, different v-myc homologs 
were identified in human and characterized as a proto-oncogene family comprising c-myc, N-
myc and L-myc genes[2, 3]. The Myc proto-oncogene family (c-Myc, N-Myc and L-Myc) has 
been studied for more than 35 years in cancer biology. Myc Transcription factors (TF) 
regulate about 15% of protein coding genes and have been implicated in regulation of 
different biological functions, such as cell proliferation, differentiation, metabolism and 
apoptosis[4-7]. In humans, the Myc protein family is associated with different types of 
cancers. While MycN deregulation is found in neuroblastoma and some other childhood 
cancers [8], MycL is involved in small lung cell cancers [8]. However, altered expression of 
c-Myc is frequently found in many different cancer types [8-10]. 
1.2 MYC STRUCTURE AND DNA BINDING SITES 
Myc is a basic Helix-Loop-Helix Zipper (bHLHZ) protein, which heterodimerizes with the 
MAX protein (bHLHZ) to regulate its target genes[11, 12]. To function as a regulatory 
transcription factor, the monomers assemble on the DNA and Myc-MAX heterodimers bind 
to the canonical (5´-CACGTG-3´) or non-canonical (5´-CANNTG-3´) DNA sequences, 
known as E-boxes [7, 12]. Different Myc family proteins bind to the same site in DNA, while 
c-Myc has an omnipresent expression in different cell types, MycN and MycN are expressed 
during specific embryonic stages and later in specific tissues [13]. Levels of Myc expression 
are crucial for early embryonic development whereas, deletion of either N-Myc or c-Myc is 
lethal at day 9-11 in mouse embryos [14, 15]. 
1.3 MYC ACTIVATION  
Myc expression is regulated by a wide range of mitogens, growth factors and cytokines that 
induce proliferation and modulate cell differentiation[16]. On the other hand Myc down 
regulation is associated with stimulation of differentiation or anti-proliferation signals[17]. As 
mentioned, Myc has a broad influence on the expression of protein coding genes (15%) 
transcribed by RNA Polymerase II, and many of these are involved in protein synthesis. 
However, increased protein synthesis requires production of all components of ribosomes 
including rRNA and tRNA. It is thus of interest that unlike most transcription factors, Myc is 
a direct regulator of tRNA and rRNA genes transcribed by RNA Polymerases I and III in 
addition to its regulation of protein coding genes [4, 5, 18-21]. In general, Myc can alter gene 
expression and histone marks of its target genes, by recruiting chromatin regulatory 
complexes via its N-terminal domain, including TRRAP, TBP, GCN5 and Tip60 [22-26], 
which locally modify histone H3 and H4 acetylation [27]. 
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1.4 The Myc protein and its cellular functions  
1.4.1 Myc functional domains 
The Myc proteins consist of two main domains, the N-terminal transactivation domain (TAD) 
and the C-terminal domain (CTD). An 84 amino acid region of the CTD domain is a bHLHZ 
region which is essential for Myc heterodimerization with MAX protein and specific binding 
to DNA sequences, known as E-boxes (5´-CACGTG-3´)(Figure 1). Mutations or the 
interaction with other proteins to the bHLHZ of Myc can lead to the loss of association with 
Max and blocking of Myc transcriptional activity[7]. 
1.4.2 Myc-Box I 
Myc, like most transcription factors, has a conserved DNA-binding domain, which is in the 
CTD of Myc. However, Myc also has several evolutionary conserved regions  in the N-
terminal domain known as  Myc homology boxes [13].  The TAD domain of Myc has two 
conserved regions known as Myc-Box (MB) I and MBII (Figure 1), which were earlier 
shown to be required for Myc induced transformation activity [28]. MBI (amino acid 45-63) 
is a binding site for several proteins that contribute to Myc activation and degradation (Figure 
1)[6, 29]. Threonine 58 (T58) and Serine 62 (S62) are important Myc phosphorylation sites, 
where S62 phosphorylation stabilizes and activates Myc while phosphorylation of only T58 
targets Myc degradation via Fbw7 (E3 ubiquitin ligase) (Figure 3) [30, 31]. The Myc half-life 
is about 24 minutes and mutations in the MBI region can affect its transformational activity 
by reducing its degradation [32]. Different MBI mutations have been reported in tumors, 
which can alter the turnover of Myc [33, 34]. In particular, the T58 amino acid substitution to 
alanine (T58A) and isoleucine (T58I) are reported in lymphoma tumors and their functional 
differences were characterized in different cell lines [32, 34, 35]. T58 mutations can alter 
Myc phosphorylation, Fbw7 dependent degradation and thus increase Myc half-life (T58A 
≈60 min and T58I ≈30 min), contributing to Myc induced transformation [31, 32]. 
1.4.3 Myc-Box II 
MBII plays a major role in Myc transcriptional activities by recruiting different co-factors 
such as TIP60, SKP2 and TRRAP (Figure 3)[6].  While MBII deletion (MycΔMBII) causes 
G2 arrest in cells and causes defective Myc transcriptional activity, cellular transformation 
and apoptosis, the mutant protein can partially induce proliferation [31, 36]. Thus, gene 
expression studies of MycΔMBII found that 90% of Myc target genes were affected by MBII 
deletion in comparison with WTMyc [36]. Deletion of MBII and MBI can inhibit TRRAP 
(TRansactivation/tRansformation Associated Protein) binding to Myc. TRRAP is an essential 
co-factor needed for Myc to induce transformation and transcriptional activity [23]. However, 
some Myc target genes are regulated independently of Myc-TRRAP binding, as shown in the 
MycΔMBII cell line [36]. 
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1.4.4 bHLHZ and MIZ-1 mediate repression 
Although Myc is known as a transcriptional activator, recent studies demonstrate that Myc 
can function as a transcriptional repressor by binding to Miz1 (Figure 3) and blocking MIZ-1 
target gene transcription[6]. Myc-Max binds to MIZ-1 and inhibits P300 recruitment by MIZ-
1 on its target genes by further recruitment of DMNT3a (DNA methyltransferase)[6, 37]. On 
the other hand, recent studies uncover MYC-MIZ-1 target genes independently of Myc and 
MIZ-1 binding sequence[37]. The same study found Myc repressed genes had E-boxes in 
promoters that lacked MIZ-1 binding sites but were enriched in SP1 binding site[37]. All 
together, these findings suggest that Myc modulating transcriptional repression is affected by 
Myc-MIZ-1 ratio and other protein interaction[37].   
 
Figure 1. Domains of Myc and their binding proteins. The N terminus of Myc has three highly conserved elements, 
known as MycboxesI–III. The C terminus contains the basicregion/helix–loop–helix/leucine-zipper (BR/HLH/LZ) 
domain. T58, S62 and T71 are known phosphorylation sites of Myc, and are targeted by glycogen synthase kinase-3 
(T58), MAP kinase (S62) and Rho-dependent kinase (T71), respectively. The domains of Myc that interact with specific 
binding proteins are shown above the full-length protein structure. If the interaction results in Myc-dependent 
transactivation, the domain is represented in green. If the interaction results in Myc-dependent repression, the domain is 
shown as a red bar, and if protein interaction results in the repression of Myc function, the domain is represented in blue. 
Interactions that mediate both transcriptional activation and repression by Myc are indicated by a dashed bar. Domains of 
Myc that bind with partner proteins for which a role has not yet been determined are shown in grey. FWB7 is not a 
transcriptional cofactor, but is part of an E3 ubiquitin ligase that regulates Myc protein stability. SKP2 functions as part of 
an E3 ubiquitin ligase and as a cofactor for Myc. p300 is a histone acetyltransferase and p400 is a histone exchange factor. 
TIP48 and TIP49 are hexameric ATPases that are part of chromatin remodelling complexes, whereas TIP60 is a histone 
acetyltransferase complex. TRAPP, an adaptor protein, is the core subunit of the TIP60 and GCN5 complexes. Med, 
Mediator. (From Adhikary et al., 2005 with permission from Nature Reviews Molecular Cell Biology) 
 
1.5 Myc control of cellular behaviors  
Myc has an important role in regulation of different cellular activities, which can determine 
cell fate. Therefore, in normal cells Myc needs to be tightly regulated through Myc gene 
transcription as well as its protein stability and deregulation of its partner proteins[6, 31]. 
1.5.1 Cell cycle 
Myc plays an important role in cell cycle regulation. Low Myc activity is associated with 
extended G1/G2 phases and delays of cells entering the S or M phases, respectively [38]. In 
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particular, Myc regulates cell cycle in the late G1 phase by inducing expression of the Cyclin 
D1/D2/E, CDK 1/2/4 and EF2 genes which are necessary for cells to enter S phase [39]. 
1.5.2 Apoptosis 
In normal cells, inappropriate deregulation of Myc induces cell proliferation and growth but 
also apoptosis. Myc can induce apoptosis via both the intrinsic (p53-dependent) and extrinsic 
(mitochondrial) pathways [40].  Myc’s effect on the intrinsic pathway involves either direct 
regulation of p53 or indirect regulation of p53 through P19ARF up regulation[41, 42]. While 
p53 regulates pro-apoptotic proteins such as PIG3, PUMA and BAX it can also arrest the cell 
cycle by up regulation of the P21CIP1 gene[43, 44]. In the case of the mitochondrial 
apoptosis pathway, Myc over-expression induces down regulation of BCL family proteins 
such as BCL2 and BCLXL that eventually leads to mitochondrial release of cytochrome c 
into the cytoplasm, thereby killing the cell[11].  
1.5.3 Transformation 
Myc overexpression alone may not be sufficient for cellular transformation, since Myc 
induced apoptosis plays a crucial role in preventing transformation [40]. Studies in 
lymphoma free individuals and Eµ-MYC transgenic mice suggest that factors in addition to 
translocation and over expression of Myc are needed [45-51]. Studies in rodent cells suggest 
that over-expression of either the RAS oncogene or anti-apoptotic protein Bcl2 can inhibit 
Myc induced apoptosis, leading to cellular transformation in cells with deregulated Myc [52, 
53]. However, in transgenic mice models with tumors, Myc repression results in cell cycle 
arrest, differentiating back to normal appearing cells and apoptosis, which lead to tumor 
regression and extended life span [54]. 
1.5.4 Degradation 
Myc transcriptional activation is finely tuned in normal growing cells. Myc over-expression 
may lead to Myc auto-regulation in a negative feedback loop, coupled with Myc 
ubiquitination and acetylation[6]. The Myc half-life time is short (approximately 24 min) 
[32], as it is a target for several E3 ubiquitin ligases such as Fbw7 and Skp2 [31]. Myc 
regulation by SCFFbw7 ((SKP-Cullin-F-box) RING-FINGER domain ubiquitin ligase 
complex) [55] depends on phosphorylation of T58 and S62 amino acids in the MBI sequence, 
which is recognized by Fbw7[56, 57]. During growth factor stimulation of cells, S62 
phosphorylation (pS62-Myc) increases Myc stability and activity [31, 58, 59]. However, 
phosphorylation of S62 facilitates T58 phosphorylation by GSK-3ß [60]. T58 
phosphorylation destabilizes Myc via Pin1 facilitated protein phosphatase 2A-B56a mediated 
dephosphorylating of S62 [61]. Singly phosphorylated Myc (pT58-Myc) is a substrate for 
Fbw7 ubiquitin ligase, which targets degradation by proteasomes (Figure 2) [30, 57]. Skp2 
recognizes Myc in both N-terminal (MBII) and C-Terminal (HLH-LZ) domains and mediates 
Myc degradation independently of Myc phosphorylation status (Figure 2)[62, 63]. On the 
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other hand, Skp2 can promote Myc transcriptional activity and induce S phase entry of the 
cells [63], which suggests a constitutive role for Skp2 promoting Myc activities and 
controlling Myc level at the same time. Myc interacts with protein acetyltransferases such as 
CBP/p300 and Tip60[64, 65]. Myc acetylation in multiple residues can increase its stability 
and interfere with its ubiquitin-mediated degradation[31, 64, 66]. Moreover, Myc expression 
can directly regulate the SIRT1 gene, SIRT1 is a protein deacetylase, which can de-acetylate 
Myc (unstable form) and thus controls its level in a negative-feedback loop [67]. 
 
 
 
Figure 2. Regulation of Myc function by Ras dependentcsignalling pathways.  The stability of Myc is regulated by the 
phosphorylation of residues Ser62 (S62) and Thr58 (T58) following stimulation by Ras-dependent signalling cascades. 
Ras stabilizes Myc by phosphorylation of S62 through the MAPK/ERK pathway and by the inhibition of glycogen 
synthase kinase-3 (GSK3) through phosphatidylinositol 3-kinase (PI3K) signalling. GSK3 can phosphorylate T58 if S62 is 
phosphorylated. Phosphorylated T58 is recognized by the prolyl isomerase (PIN1), which leads to the isomerization of 
Pro59 and enables phosphatase-2A (PP2A) to remove the phosphate residue from S62. SCFFWB7 (FBW7 in the figure), a 
ubiquitin E3 ligase, polyubiquitylates Myc in a T58-phosphorylationdependent manner and labels it for degradation by the 
proteasome (From Adhikary et al., 2005 with permission from Nature Reviews Molecular Cell Biology) 
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2 MYC EVOLUTION, SEQUENCE OR PROTEIN 
STRUCTURE? 
2.1 Myc evolution and protein sequence 
Transcription factors are important coordinators of development in multicellular organisms, 
and are involved in regulation of their biological processes. Transcription factors exhibit a 
complex network of interactions with proteins and DNA. Subsequently, TFs are well known 
to recruit other co-factors as well as themselves being recruited by their partner proteins to 
specific sequences of target genes, thus determining patterns of gene expression. 
Understanding a transcription factor family and its conserved regulatory motifs in different 
species, can give key understanding of its role in regulating mammalian cell fate and function 
as well as the altered pathways that characterize cancer cells. 
Myc belongs to a super family of bHLH proteins, which can bind to heterodimerization 
partners via their bHLH domain and play important roles in development of both vertebrate 
and invertebrate metazoan organisms [68, 69]. Recent genome sequencing and functional 
studies in the unicellular Monosiga berevicollis report a functional Myc homolog and expand 
these ancient TFs to a time before the evolution of metazoans[70, 71]. Previous studies report 
the C-terminal bHLH-LZ domain (CTD) as the main evolutionary conserved region of all 
Myc family proteins [72]. Moreover, vertebrates have a distinctive conserved site in bHLH 
DNA binding and dimerization region[73]. 
Myc family proteins are highly diverged TFs in the N-terminal sequences that lack high 
propensity for structure formation. Due to this fact, using classical protein multiple alignment 
methods gives a poorly connected phylogenetic relationship for Myc family proteins outside 
mammalian organisms. However, previous phylogenetic studies of bHLH TFs used C-
Terminal conserved domains of Max family proteins [72]. These are more successful at 
grouping Myc proteins in relation to more distantly related bHLH TFs but they may of course 
lack important information needed for accurate phylogenetic characterization within the Myc 
protein family. Myc proteins have 6 blocks of conserved residues through their protein 
sequences[13]. In vertebrates, Myc proteins have 3 main highly conserved blocks in the N-
terminal region, which are also found in most Eumetazoans except within the Mandibulata 
(e.g. fruit fly species). However, fruit fly dMyc has been experimentally shown as a valid 
Myc homologue. The dmyc gene is important for regulation of growth and development, and 
dMyc deregulation is correlated to changes in both fruit fly cell size as well as their body size 
[74]. Outside vertebrates, one or more motif matches are insufficient for reliable detection of 
Myc proteins. Furthermore, the N-terminus of choanoflagellate (M. brevicollis) Myc proteins 
is generally very poorly connected to mammalian Myc proteins but interestingly it does have 
some similarity to MBI and MBII residues (Paper I), which provides some evidence that 
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these regions of Myc proteins may have a conserved function throughout the evolution of 
Myc proteins [70-72]. 
 
2.2 Intrinsic disorder profile of proteins, new insights on evolution 
Myc as well as other transcription factors (TFs), has a certain region within their protein 
sequences or the whole TF, lacking defined structural conformation in physiological 
conditions[75]. In general, proteins can have well-structured domains as well as unstructured 
regions that are termed, Intrinsically Disordered Region (IDR) [76]. Proteome-wide analysis 
shows that many of the TF interaction domains are within IDR regions of the proteins[77]. 
Consistently, previous reports imply that, upon binding to other partner proteins IDRs could 
locally fold, such that appropriate conformation changes can induce protein-protein complex 
formation[76]. More recently, short structural elements (10-20 amino acids), which are 
functional in protein-protein and protein-DNA recognition of the proteins, have been 
identified in proteins [78, 79]. These elements, MoRF (Molecular Recognition 
Feature)/ANCHOR, can be conformationally stabilized by partner proteins and thus transit 
from disordered to an ordered conformation [77, 79]. Thus, this flexible nature of IDR 
regions is important for high specificity and low affinity of TF binding to multiple bind 
protein partners[77].  
Furthermore, recent studies identified an evolutionary conserved pattern for IDR regions in 
mammals, suggesting the core functional definition of a protein is conserved through its rapid 
IDR evolution [80]. 
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3 RIBOSOME BIOGENESIS 
Ribosomal RNA (rRNA) is the major product of RNA synthesis in growing mammalian 
cells. In actively growing cells, about 35% of transcriptional activity is devoted to rRNA 
synthesis and a large part of the mRNA transcription pool encodes proteins essential for 
rDNA transcription and ribosome assembly [81, 82]. Together, these transcripts unite to 
provide the machinery needed for protein synthesis and cell growth [82]. 
In mammals, ribosomes have two distinct subunits referred to 60S and 40S. 60S is the larger 
subunit of the ribosome and contains around 49 ribosomal proteins together with the 28S, 
5.8S and 5S rRNAs [83, 84]. On the other hand, the smaller 40S subunit consists of 33 
ribosomal proteins and the 18S rRNA [83, 84]. rDNA is transcribed by RNA Polymerase I 
(Pol I) and Pol III. Whereas, RNA Polymerase III transcribes 5S rRNA, Pol I transcribes a 
47S precursor ribosomal RNA which is later cleaved to the mature 18S, 5.8S and 28S rRNAs 
through exo- and endo-nucleolytic cleavages [85]. RNA Pol II transcribes ribosomal protein 
genes and other additional factors [86].  
The nucleus contains multiple copies of rRNA genes (Figure 3). The genomic regions 
containing rRNA genes in human cells are clustered in the nucleolar organization region 
(NORs) of chromosomes 13, 14, 15, 21 and 22, which combine together in growing cells to 
constitute the nucleolus [87-90]. Importantly, morphological and functional changes in the 
nucleolus are diagnostic markers of particular tumor types and states [91]. These 
morphological changes include the number of nucleoli per nucleus, nucleolus size and shape 
as well as its “chromatin texture” [91]. Changes in nucleolar phenotype are the consequence 
of an increasing need of ribosome biogenesis in highly proliferative cells including cancer 
cells, and changes in rRNA expression appear to be an important mechanism in tumor 
genesis [91].  
 
 
Figure 3. c-Myc binds to rat rDNA and directly induces rDNA expression (a) The sequence and distribution of E-
boxes in the rDNA is strongly divergent between humans and rats. The upper diagram shows human rDNA derived from 
GeneBank no. U13369, containing the transcribed and untranscribed regions of the rDNA repeat unit. The lower diagram 
shows rat rDNA, derived from accession numbers X04084, X03838, X61110, X00677, X16321, V01270 and X03695. 
Dotted sections of the diagram represent regions where rat sequence information is incomplete. Locations of E-boxes are 
marked with vertical lines. The percentage identity between human and rat sequences is noted for each coding and non-
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coding section. Horizontal bars represent regions amplified in chromatin immunoprecipitation (ChIP) assays in rat cells, 
and labels indicate their approximate position relative to the transcription start site (R0).(Shiue et al., 2009 with the 
Permission from Oncogene “springer Nature”)  
3.1 Mammalian nucleolus structure and rDNA  
Mammalian cells have three main nucleolus compartments including Fibrillar Centers (FCs), 
the Dense Fibrillar Component (DFC) and the Granular Component (GC) (Figure 4) [86, 92]. 
Transcriptionally active cells have different numbers of small FCs, while cells with reduced 
protein biogenesis have one large FC [93]. Nascent rRNA transcription occurs in the region 
between FCs and DFCs, causing the later accumulation of pre-rRNA (47S) in the DFC 
compartment where nucleolytic cleavage of the 47S transcript occurs (Figure 4) [94]. 
Moreover, intra-nucleolus migration of the 18S, 5.8S and 28S rRNA and synthesis of 
ribosomal subunits occurs in the GC [94]. 
The diploid human genome contains around 400-repeated ribosomal RNA genes, mainly 
arranged as tandem head to tail clusters, from telomere to centromere, in NORs [85, 90, 95]. 
In human cells, each 43 kb rDNA repeat has an approximately 13kb sequence encoding pre 
ribosomal RNA (47S) and each repeat is separated from the next by ≈ 30kb of intergenic 
spacer (IGSs) DNA sequence (Figure 3) [90]. However, both transcribed and non-transcribed 
sequences of pre-rRNA are necessary for recognition and binding of the Pol I pre-initiation 
complex and subsequent rDNA transcription[81]. In particular, the regions including 
proximal-spacer promoters, enhancer and terminators have been shown to be important [96]. 
3.2 Nucleolar scaffold and DNA compartmentalization 
Early genome organization and electron microscopy studies suggest a dynamic link between 
nuclear structures and gene expression [97, 98]. The nucleus has structural compartments 
including nucleoli, the nuclear envelope and the nuclear matrix. Further, the organism’s 
chromosomes are located within the nucleus. Association of a genomic location with nuclear 
structures can influence the transcription of that genomic region [99]. Disorganization of 
nuclear structural compartments, including the nucleoli, nuclear envelope and nuclear matrix 
is associated with cancers [100, 101]. 
Within the nucleus, genes inside widely separated chromosome territories can loop and co-
localize into structurally distinct active transcription sites [102, 103]. In these active 
transcription sites, often termed “transcription factories”, DNA loops are surrounded by 
transcription factors, RNA polymerases and other auxiliary co-factors [104]. 
Nuclear matrix is an intra-nuclear structure that provides a protein-supporting scaffold for the 
diverse processes and functions, including gene looping, DNA transcription and RNA 
processing [97, 105]. DNA sequences, which mediate loop formation, are known as Scaffold 
Attachment Regions or Matrix Association Regions (S/MARs) [105]. Accordingly, multiple 
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loop structures are maintained as domains due to end attachment of the S/MAR regions to the 
nuclear matrix scaffold [106-110].  
Interestingly it has been speculated that repetitive non-transcribed elements of rDNA genes 
(IGS segments) can play a role in the induction of higher-order rDNA structure [85], which 
will be discussed in section 3.4 . Moreover, it has been shown by three-dimensional electron 
microscopy that compact active rRNA genes within fibrillar center (FCs) have loop structures 
in the form of the well-known Christmas tree structure [111].  
 
Figure 4. LEFT: Nucleolus of a human Sertoli cell. Technique as in Fig. 2 with additional acetylation. The single large 
fibrillar centre (c) is surrounded by strands of dense fibrillar component (d) sometimes intermingled with granular component 
(d-g) Dense fibrillar component is also found at the periphery of a distinctly defned feld of granular component (g) and at a 
great distance from the fibrillar centre, x 30,000.RIGHT: Human Sertoli cell nucleolus. Electron microscopic in situ 
hybridization of rDNA. The 5-nm gold particles of the label are marked with indian ink. The original preparation is published 
in Schwarzacher and Wachtler (1991). Density of label above background is seen only in the region of the dense fibrillar 
component. x 30,000. (Hans Georg Schwarzacher and Franz Wachtlerwith (1993) with permission from Anatomy and 
Embryology) 
3.3 Ribosomal RNA gene transcription 
The rDNA promoter consists of two main binding elements, the upstream control element 
(UCE) and the core promoter [112]. In general, transcription initiation of rRNA genes needs 
assembly of specific complexes at their promoters including, RNA Polymerase I, upstream 
binding factor (UBF), transcription initiation factor 1A (TIF1A), and the selectivity complex 
1 (SL1) [81]. The most important step in rRNA gene transcription is the recruitment of Pol I 
to the rDNA promoters, which is a limiting factor in pre-ribosomal RNA (47S) biogenesis 
[81]. Pol I recruitment to the rDNA promoters is achieved by its recruitment to the Pol I pre-
initiation complex[81]. Such complexes are formed by UBF and SL1 interacting together, 
whereas UBF alone can bind to the multiple sites on rDNA repeats, via the minor groove of 
the DNA, and forms a nucleosome like structure and can recruit the other complexes [81, 
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113]. Upon UBF-SL1 complex binding to the UCE and the core promoter of rRNA genes, it 
can further interact with and activate TIF1A [95, 114, 115]. Thereafter, the pre-initiation 
complex can recruit Pol I to the rDNA promoters and initiate 47S ribosomal DNA 
transcription [81]. The 47S precursor ribosomal RNA is later cleaved and generates the 
mature rRNA subunits (18S, 5.8S and 28S) [85]. 
RNA Polymerase III transcribes the fourth rRNA subunit (5S rRNA) [81, 116]. Pol III 
transcribed genes require (Transcription Factor for Polymerase III) TFIIIC-TFIIIB 
recruitment to their promoters [117]. However, TFIIIC- has a low affinity for 5S rRNA 
promoters and Pol III transcription is therefore dependent on TFIIIA binding to the 5S RNA 
promoter regions [81]. Ordered recruitment of TFIIIA, TFIIIC and TFIIIB to the transcription 
start site are required for Pol III loading and transcription initiation of 5S RNA [81, 117].  
3.4 Role of Myc in rDNA transcription 
In eukaryotes, ribosome biogenesis requires all three major RNA polymerase activities. Pol I, 
only transcribes rRNA genes and produces pre-RNA (47S). Pol III, transcribes some small 
non-coding RNAs as well as 5S rRNA and transfer RNAs (tRNA), both of which are 
essential for ribosome biogenesis and protein production [81]. Pol II, transcribes genes 
(mRNAs) that encode ribosomal protein subunits, accessory factors, Pol I and Pol III subunits 
and their co-factors [81]. Pol I and Pol III transcriptional activates represent the majority of 
nuclear transcription [81]. Moreover, transcription of Pol I and III subunits and co-factors 
increase in different cancer cells [81, 116, 118]. On the other hand, Myc oncoprotein and 
other tumor suppressors can modulate rDNA transcription [116, 118]. Accordingly, 
Drosophila Myc (dMyc) was found to play a role in ribosome biogenesis [119]. Moreover, a 
recent microarray study, elucidated ribosome biogenesis as the Myc core signature in cancer 
cells, independent of cell type and species [120]. Myc’s role in ribosome biogenesis, by 
regulating transcriptional activity of all three RNA polymerase is briefly described in Figure 
5. 
We, at the same time as another group, found that Myc regulates Pol I, independently of its 
Pol II transcriptional activities [20, 21, 120]. Moreover, we revealed that Myc could localize 
to the nucleolus, bind to E-box motifs and promote rDNA transcription [20]. In Myc-ER rat 
fibroblasts, where Myc is fused to part of the estrogen receptor and is dependent on addition 
of estrogen agonists for its activity, absence of Myc activity reduces rDNA transcription by 
15-20% compared to the wild type cell line (TGR1) [38]. Addition of agonist ligand to Myc-
ER cells to induce Myc activity increased rDNA transcription [121]. Myc can regulate pre-
rRNA synthesis by direct binding and regulation of UBF, SL1 and Rrn3 (TIF1A) complexes 
on the rRNA genes [81]. However, a variety of Chromatin immune precipitation (Chip) based 
studies show Myc binding to the UBF and Rrn3 (TIF1A) gene promoters [122, 123]. In the 
mouse model, Myc expression induced Pol I specific subunit transcription as well as 
transcription of genes encoding the UBF and SL1 subunits (TBP, TAF1C, TAF1D) [122]. In 
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addition, Myc can recruit TRRAP (TRansformation/tRanscription Associated Protein), which 
has a histone acetyltransferase co-activator function, via the MBII domain [22, 124]. 
Interestingly, Myc localization to the nucleolus can influence the Pol I target gene by altering 
its histone H3 and H4 acetylation, in both the transcribed and non-transcribed (IGS) regions 
of the rRNAs genes [20, 21].   
As for Pol I, Myc can regulate around 40% of Pol III subunits as well as its target genes 
including 5S rRNA [81, 116, 122]. The transcriptional level of 5S rRNAs increases upon 
Myc induction in different cell types and tumors [125-127]. Myc can directly influence Pol 
III transcription by its interaction with the TFIIIB subunit known as Brf1, which is the 
limiting factor of Pol III transcription [125, 128]. Importantly, Myc increases histone H3 and 
not H4 acetylation on pol III target genes, possibly via the Gcn5 acetyltransferase that 
associates with the TRRAP co-factor [124]. 
As previously discussed, rRNA genes within fibrillar center (FCs) can form loop structures 
[111]. And recently, we have discovered that Myc could play an alternative role in ribosomal 
biogenesis by inducing loop structures and thereby altering the higher order chromatin 
structure of the rDNA repeats of growth stimulated cells [121]. Upon serum stimulation of 
quiescent rat fibroblast cell lines, which induces Myc level and leads to a subsequent increase 
in the binding of the Pol I and TBP (an SL1 complex subunit) in both upstream core promoter 
sequences and downstream of the transcribed region in the IGS region [121]. Thus, c-Myc 
can induce a chromatin hub, where rRNA gene loops are linked by promoter and terminator 
regions in close proximity that could be a mechanism for enhancing re-initiation of rDNA 
transcription. 
 
 
  
 15 
 
Figure 5. Myc regulates Pol I and and Pol III at multiple levels to stimulate protein synthesis and cell growth 
(Kirsteen J. Campbell and Robert J. White (2014) with copyright permission from Cold Spring Harbor 
Laboratory Press Cold Spring journal). 
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4  ROLE OF MYC IN LYMPHOMA MALIGNANCIES 
4.1 Lymphoma malignancies  
Lymphocytes are fundamental immune cells circulating in blood and the lymphatic system. 
In health (non cancer) individual B (bursa or bone marrow) and T (thymus) lymphocytes 
represent 20 to 45% of white blood cells [129]. B and T cells are an important component of 
the human innate and adaptive immune systems [130, 131]. Lymphocytes are the origin of a 
diverse group of hematological malignancies, which are classified by their cells of origin and 
their pathological characteristics [132].  
According to the World Health Organization (WHO) in 2016, lymphoid neoplasms are 
classified into five major groups. These are 1. Mature B-cell lymphoma neoplasms including 
Burkitt’s lymphoma, 2. Mature T and NK cell neoplasms, 3. Hodgkin-lymphoma, 4. Post 
transplants lymph proliferative disorders (PTLD) and 5. Histiocytic and dendritic cell 
neoplasms [133]. 
4.1.1 T cell lymphocyte 
Bone marrow is the niche where most hematopoietic cells are generated and complete their 
development. Unlike other bone marrow (BM) derived hematopoietic cells, T-cell 
progenitors migrate into the thymus and further undergo lineage commitment, selection and 
maturation [134, 135]. Several developmental stages of T lymphocytes are phenotypically 
characterized by their patterns of co-receptor expression. T-lineage progenitors give rise to 
the CD4-CD8-  double negative thymocytes, in which T-cell receptor recombination starts and 
T-cells start the maturation stage and become double positive (DP) CD4+CD8+  thymocytes 
[134, 135]. At this stage, DP cells have rearranged TCRα genes and undergo CD4 or CD8 
lineage transformation that includes both positive and negative selection processes[134, 135]. 
Such mature T-cells (Naïve T-cells) are then released into peripheral blood [135].  
In peripheral blood T-cells account for around 75% of the lymphocytes and T-cell activities 
play a major role in cell-mediated immune responses [129]. Naïve T-cells are mainly 
classified into three different lineages including; 1. CD4+ T-helper cells, which are mainly 
involved in immune responses by releasing cytokines 2. CD8+ T-cytotoxic cells, which 
directly destroy their targets by antigen recognition via their surface receptors directed against 
cancer cells or infectious agents 3.T-supressor cells, a regulatory T-cell linage that is 
important in autoimmune tolerance against self antigens [130, 136, 137]. 
4.1.2 B-cell lymphocytes  
The B-cell lineage is derived from the development of hematopoietic stem cells in the bone 
marrow niche, and plays a major role in adaptive immunity[131, 138]. The B-cell system is 
considered as a positive regulator of immune response by antibody production[129, 131]. 
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Each B-cell can proliferate in response to specific stimulation and later produce plasma cells, 
which are able to produce only one species/type of antibody [131, 139]. However, B-cells can 
function in different immunological responses including antigen presentation activities in the 
lymph node [140] as well as in cytokine production (e.g. IL-10, TNFα, IL-6 and IFNγ) [141, 
142]. 
In human, immature B cells pass different stages of developments in BM independently of 
antigen stimulation [131, 139]. In particular, progenitor B-cells (pro-B-Cells) mainly require 
hematopoietic stem cell stimulation by stromal cell products, mainly interleukin 7 (IL-7) and 
activation by fms-like tyrosine kinase 3 [139]. During BM development stages, pro-B-cells 
differentiate to precursor B-cells, in which B-cells acquire their sequential light and heavy 
chain rearrangements, leading to formation of the B-cell Receptor (IgM). At this point they 
have reached the immature B cell stage [131, 138, 139]. At the immature stage, B-cells leave 
the BM and enter the periphery blood, where they further complete their development to 
mature B cells co-expressing IgD and IgM on their cell surface[131, 139]. Mature B cells 
migrate to the lymphoid organs, where as their differentiation to mature memory B cells or 
antibody secreting plasma cells occurs, in antigen dependent manner [138, 139].  
4.2 Introduction to Burkitt’s Lymphoma  
In 1985, Dr Denis Burkitt first characterized a tumor in children, which was later identified as 
a pathological syndrome, known as Burkitt’s Lymphoma (BL) [143]. BL is a highly 
proliferative non-Hodgkin’s B-cell lymphoma, which histologically has multiple nucleoli per 
nucleus [144]. BL has three epidemiologically recognized variants, including endemic BL, 
sporadic BL and a HIV/EBV associated immunodeficiency form [145]. 
In endemic areas BL accounts for around 50% of children with non-Hodgkin lymphomas and 
is mostly located in facial bones [144]. Moreover, the endemic variants are associated with 
either or both EBV and malaria infections [146]. In comparison, sporadic BL represents 
around two percent of adult lymphomas in develop countries and they mostly involve 
lymphoid tissues of different organs including the gut and the respiratory tract [146]. 
4.2.1 Myc regulation in Burkitt’s Lymphoma 
Early chromosome karyotyping observations in BL tumors revealed an additional band at the 
end of chromosome fourteen, as well as the absence of a band in chromosome eight [147]. 
This t(8;14)(q24;q32) translocation is observed in more than 85% of BLs, independently of 
their origin [146]. Later, independent groups found that the region containing the myc gene 
(8q24) was translocated to the immunoglobulin heavy chain locus [2, 148] or to the 
immunoglobulin light chain locus [149].  
Myc deregulation resulting from the t(8;14)(q24;q32) translocation is the diagnostic hallmark 
of BL tumors. myc gene translocation and deregulation sometimes followed by its 
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rearrangement or mutation is associated with aggressive lymphoid neoplasms, including BL 
but also diffuse large B-cell lymphoma (DLBCL) [147, 150]. However, Myc translocation 
per se seems to be insufficient for tumor genesis in lymphoma-free individuals and cells need 
to overcome other inhibitory effects before they can develop into lymphoma cells [46]. In 
particular, deregulation of BCL6 and BCL2 are found in aggressive B cell malignancies, 
known as Double Hit Lymphoma (DHL). Moreover, Myc and p53 mutations are identified in 
more aggressive BL, and p53 mutation in DHL, harboring deregulated Myc and BCL 
proteins is associated with even more aggressive lymphoma [151, 152].  
In addition to the chromosomal abnormalities, 60% of BLs have missense mutations in Myc 
clustered in functional domains, primarily Myc Box I (MBI) [32, 147]. This suggests a 
selective adaptation of the Myc protein in Myc driven lymphomas. MBI Mutations, including 
E39D, A44V, P57S, T58I, T58A, can affect the conserved MBI region and alter the predicted 
conformation of the Myc protein in some cases (Paper I) [35, 153]. 
Previous studies in rat fibroblast revealed that these mutations have different oncogenic 
effects on the Myc protein[35]. Importantly, Threonine 58 to Alanine substitution (T58A) 
enhances Myc transformation activity while it reduces Myc induced apoptosis [35]. In 
contrast, T58 to Isoleucine substitution (T58I) has the opposite biological effect on Myc, by 
reducing its transformational activity and having no noticeable difference on Myc-dependent 
induction of apoptosis, compared to a cell line expressing wild type Myc [35]. In an apparent 
contradiction to this, T58I is the most reported mutation in BLs, suggesting that different 
substitutions can be a selective step for Myc in different lymphoma cells.  
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5 MATHERIAL AND METHODS 
5.1 Lentiviruse vectors constructions  
Wild type c-Myc, T58AMyc and T58IMyc DNA was generously provided by M.D Cole 
(Department of Genetics, Geisel School of Medicine at Dartmouth, USA) cloned in Cßh-Myc 
vectors (Figure 6) that were first sent for sequencing using a 
5´ATGCCCCTCAACGTTAGCTTC 3´primer to confirm the correct wild type or mutant 
sequences. The human WTMyc, T58A and T58I sequences were amplified by PCR using SK 
primer sets; SK-FW 5’ TCTAGAACTAGTGGATC 3’ and SK-Rev 5’ 
CGAGGTCGACGGTATCG  3’ containing BamHI digestion sites. 
 
 
Figure 6. Illustrating Cß-hMyc plasmids containing WTMyc  or Mutation including : T58AMyc and T58IMyc 
Accordingly, we opened pSIR-TREMYC-IRES-EGFP-PGK1-rtTA2 vector (generously 
provided by Kari Högstrand) using BamHI enzyme digestion at a unique cloning site. 
Amplified human WTMyc, T58A and T58I sequences were then cleaved with BamHI and 
cloned into BamHI cleaved pSIR-TRE-IRES-EGFP-PGK1-rtTA2 lenti-virus expression 
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vector, generating pSIR-TRE-MYC-IRES-EGFP-PGK1-rtTA2 vectors, as illustrated in 
Figure 7. 
 
Figure 7. pSIR-TRE-MYC-IRES-EGFP-PGK1-rtTA2 plasmid containing WTMyc , T58A or T58I fragments and other 
respective sequence regions , used for retroviral transductions  
5.2 Making the triple hit Myc-driven B-cell lymphoma-like cell system. 
Establishing a cell line with patient lymphoma cells is often difficult, since cells might not yet 
have acquired all genetic alterations require for independent cellular growth in vitro [40]. 
Moreover, inducing Myc in primary B-cells results in enhanced apoptosis. However, 
experimental approaches have been found by our collaborator (Alf Grandien), by using anti 
apoptotic proteins BCLXL and BMI1, which when overexpressed together with Myc allow 
propagation of primary B-cells, in-vitro. Briefly, The Lipofectamine 2000 system (Life 
Technologies, Paisley, UK) was used for transient transduction of the Phoenix-Eco packaging 
cells (kindly provided by GP. Nolan, Stanford University). Retroviral particles were obtained 
and concentrated by centrifugation (6000 x g, overnight at +4°C). LPS stimulated B-cells 
were transduced by retroviral pool spin infection in 8ug/ul of polybern (Sigma-Aldrich). Each 
retroviral pool contained viruses containing one of WTMyc, T58AMyc or T58IMyc together 
with both BCXL and BMI1. Cells were re-plated in complete culture medium supplemented 
with 2mg/ml Doxycycline. B-Cell Lymphoma-like development and survival depends on 
retroviral transfection with all of these three genes that alter the cell fates by overexpressing 
Myc and inhibitors of the intrinsic and P53 apoptosis pathways.  
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5.3 Design pipeline for read alignments and subtraction of human reads from 
mouse reads 
We used human c-Myc, BCLXL and BMI1 for transduction of the mouse splenic B-cells. 
Subsequently, to omit the influence of these 3 human overexpressed genes, we made a human 
mini-reference genome that was used to subtract reads of human origin. Read quality was 
assessed by Fastqc (v.0.10.1) and the reads were then aligned to the mouse genome, (build 
GRCm38.75, obtained from the Illumina iGenomes with ensemble annotation files and pre-
built Bowtie2 indexing) using the splice-aware short read aligner Tophat2 (v.2.0.4) with 
Bowtie2 (v.2.2.6), and default options with –G indicating the GRCm38.75 GTF file and –g 
set to 1 [154, 155]. Next, the raw reads for each sample were aligned by Tophat2 to a mini-
reference genome and the aligned reads were subsequently subtracted from the bam files 
containing reads aligning to GRCm38.75. 
5.4 Using PONDR®VLXT for prediction of BL-AM protein disorder profiles 
PONDR®VLXT [78, 156] predicts the disorder profile of c-Myc protein and gives residue-
by-residue predicted disorder scores. However, the PONDER-VLXT algorithm can also 
predict short ordered regions within an intrinsically disordered region. This additional feature 
of this algorithm makes it more suitable for analyzing the Myc associated cancer mutations. 
Briefly we substituted residue-by-residue disordered values into the equivalent position of 
each amino acid and data were plotted using ggplot2 package in R [157]. 
5.5 Analysis of the nuclear matrix and DNA methylation assay 
Matrix attachment region or scaffold attachment regions are AT-rich sequences, which define 
DNA sequences that bind to the extracted nuclear matrix, and are generally located in 
regulatory elements of the DNA [158, 159]. There are different methods for MAR isolation. 
In general, DNase I or a combination of restriction enzymes is used to digest nuclei. Next, 
histones and other proteins are extracted by high salt concentration (2M NaCL) or lithium 
diiodosalicylic (LIS). Thereafter, DNA sequences can be separated into an insoluble portion, 
containing matrix associated DNAs, and a soluble portion containing non-matrix associated 
DNA. Importantly, some methods suggest DNase I treatment of the sonicated nuclei before 
sucrose gradient centrifugation, in order to avoid loss of nucleoli due to their being trapped 
within a chromatin network [160]. Also, DTT addition to both digestion and histone 
extraction steps is reported to promote the solubilization of the matrix and prevent non-
specific DNA binding to the nuclear matrix[161]. 
In Rat Fibroblasts, we measured the methylation level of matrix-associated regions in the 
CpG site at the -143 position upstream of the transcription initiation site. Matrix associated 
and non-matrix associated DNAs were recovered after digestion with BamHI and XhoI, using 
additional chloroform washing steps, in order to remove residual phenol that was inhibitory 
to the methylation sensitive enzyme digestion. HpaII and MspI have the same recognition site 
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(5’…CCGG…3’), but the HpaII enzyme cannot cut methylated DNA. Therefore, we used 
this enzyme sensitivity assay and evaluated the level HpaII resistant sites by qPCR using the 
forward primer 5’ AGCATGGACTTCTGAGGCCGAG 3’ and the reverse primer 5’ 
CATAAAGCTGCCCCAGAGAG 3’.  
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6 AIMS   
 
 
• To determine the extent of conservation/ divergence of intrinsic protein disorder 
throughout the Myc protein family and to evaluate the effects of cancer-associated 
substitution mutations on the intrinsic disorder profile of. 
 
• To determine whether and how Myc changes the higher order chromatin structure of 
the rDNA by modulating its interaction with the nuclear matrix. 
 
•  To identify gene tagrets of Myc that are important during development of a 
lymphoma phenotype in B-cells as well as how this is augmented by cancer-
associated Myc mutants. 
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7 RESULTS 
7.1 Paper I: phylogenetic and molecular evolution studies of the Myc family 
proteins. 
To understand Myc evolution and its role in cancer, we used the intrinsic disorder profile of 
Myc family proteins as a signature to analyze their structural evolution, as well as the 
adaptive effect of Burkitt Lymphoma-Associated Mutations (BL-AM) on the intrinsic 
disorder profile of the c-Myc protein. In particular, we revealed that the IDR profiles of Myc 
proteins are a primordial signature within the evolution of Myc in organisms ranging from the 
Protista to the broad range of Metazoans. Further, our findings suggest that adaptive BL-AM 
can affect the intrinsic disorder profile of the c-Myc protein.  
To understand Myc structural evolution, and the functional role of its adaptive cancer 
mutations we first used BLASTP and identified representative metazoan Myc protein 
sequences in the UniProt Ref50 dataset. Here we illustrate UniRef50 Myc group’s similarities 
to several defined c-Myc (P01106) signatures. And we further run multiple-alignments for 
phylogenic analysis of the UniRef50 groups (representative Myc protein sequence) in 
Metazoans, where our dendrogram trees show the clades for c-Myc, L-Myc, N-Myc and d-
Myc (fruit fly-Myc). However, most other Myc proteins are poorly connected to the 
dendrogram with low statistical support. 
To have a better understanding of Myc protein evolution, we used an alternative approach by 
comparing Myc proteins by their predicted intrinsic disorder profiles. Thus, we used a variety 
of algorithms for in-silicon prediction of the intrinsic disorder region profiles (IDR) of Myc 
proteins. We revealed that all Metazoan Myc proteins are highly disordered proteins. 
Subsequently, we used a systematic analysis of Myc disorder predictions (IDR) and the 
distance between the scores for different Groups of UniRef50 representative Myc proteins for 
phylogenetic analysis. Interestingly, using IDR scores inserted into multiple alignments of 
Myc proteins, we found a better dendrogram tree grouping most Myc proteins in individual 
clades with good support. As the results illustrate, there is good separation of c-Myc, N-Myc 
and L-Myc clades, similar to the sequence based tree, human c-Myc (P01106) and Xenopus 
Myc(Q05404) were both placed outside the N-Myc clade. Other Myc proteins, which are 
functionally related to human Myc proteins, grouped together well in clades and were well 
connected to the clades of established Myc proteins. 
Myc Box I is a main functional domain of the Myc protein and is enriched with mutations 
found in BL. The known BL-associated mutations are located in the disordered regions of 
Myc and have different functional roles in cell proliferation as well as cellular transformation 
and apoptosis [32, 35]. One of the important parts of my thesis was first to analyze the effect 
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of BL-associated mutations on intrinsic disorder structure of the c-Myc protein and to further 
study their adaptive effect on Myc functionality in my last project (Paper III). We used the 
PONDR®VLXT [78, 156] algorithm to predict and visualize protein disorder profiles of wild 
type Myc and different reported BL mutations know to alter Myc function [35]. Our in silico 
finding suggests that adaptive amino acid substitutions can locally effect the disorder of the 
Myc protein, and that different amino acid substitutions of the same residue (Threonine 58) 
effect the Myc IDR profile differently. This finding was interesting in relation to their well-
described functional differences in Rat fibroblast systems [32, 35]. Therefore, analyzing these 
missense mutations in a relevant B-cell system (Paper III) could help to couple differences in 
the effects of BL mutation on protein conformation to differences in their effects on protein 
function. 
 
 
7.2 Paper II: functional analysis of Myc family proteins in mammalian cells. 
In this study, we found a novel c-Myc role in ribosome biogenesis by its role in the enrolment 
of the rRNA genes to the nucleolar matrix. First, we predicted the potential Matrix 
Attachment Regions (MAR) in rDNA repeats, using the MAR-wiz computational tool. This 
exclusively identified the InterGenic Spacer (IGS) sequences, as the most prominent 
Matrix/Scaffold attachment sites for mammalian rDNAs. We then used Human (HeLa) and 
Rat (TGR1) cell lines, from which we isolated nucleoli by sucrose gradients, before further 
digesting the isolated nucleoli with DNase I and RNase A and PCR (Polymerase Chain 
Reaction) identification of the possible matrix protected rDNA regions. Using different 
primer sets across the 40kb rDNA sequence, we showed that the IGS regions have a high 
tendency for matrix association. 
We further monitored matrix attachment in response to the growth stimulation by serum. The 
matrix-protected region was significantly reduced in starved cells compared to the serum-
stimulated cells. However, the H16, H27, H37 and H40 regions were matrix protected in both 
serum starved and stimulated cells. Serum stimulation of the cells activates Myc. Therefore 
we inhibited Myc by treatment with a small molecule drug (10058-F4). Interestingly, Myc 
inhibition resulted in abrogated nuclear matrix protection in growth-stimulated cells, which 
suggests a role for Myc in matrix attachment of rDNA in actively growing cells.   
To further characterize S/MAR sequences and their potential matrix binding abilities in the 
formation of chromosomal loops, we established a MAR-Loop method in our lab by 
combining the MAR assay with the 3C assay without the formaldehyde crosslinking step. In 
growing HeLa cells, both 3C (Chromosome Confirmation Capture) and MAR-Loop results 
show that the upstream region of the promoters and downstream transcription termination 
region are juxtaposed to each other. Therefore, we concluded that the anchorage of the IGS to 
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the nucleolar matrix could promote rDNA loop structures. Next, we performed a Chip-qPCR 
assay in serum stimulated HeLa cells and showed physical binding sites of Myc across the 
rDNA repeats (40kb). Moreover, we used Chip-loop (3C-Chip) assays and further determined 
the physical association of Myc in the loop organization of the IGS regions.  
In general, genes can epigenetically silenced by DNA methylation as well as Histone 
modifications. In mouse cells, rRNA transcription can be regulated trough a single CpG 
methylation at -133 in their Upstream Core Elements (UCE) [162, 163]. This single 
methylation in the UCE site can inhibit UBF binding to the rDNA and epigenetically 
abrogate Pol I pre-initiation complex formation [162, 163]. We used TGR1 cells (rat cell line) 
to further determine rDNA methylation status of matrix-attached regions, by methylation 
sensitive enzyme digestion, respectively HpaII and MspI. Our results illustrate that 80% of 
matrix associated rDNA is cleaved by HpaII, in comparison with 20% cleavage in non- 
matrix associated rDNAs, suggesting that matrix associated rRNA genes are hypo-methylated 
and more available for transcription activation.   
 
7.3 Paper III: lymphoma-associated gene expression changes in an inducible 
model of Myc-driven B-cell lymphoma 
In our previous study (Paper I), we illustrated that BL mutations could differentially change 
the c-Myc protein disorder profile. Moreover, previous functional and microarray studies in 
Rat fibroblasts revealed that adaptive cancer mutations could differentially affect Myc 
functions, compared to both the wild type Myc and other mutants. To better understand 
Myc’s role in Burkitt’s lymphoma, and how this is augmented by BL adaptive mutation we 
transduced primary B-cells with lentivirus constructs that allow regulatable conversion of the 
cells to lymphoma-like cells that depend on expression of WTMyc, T58A or T58I. 
Over-expression of the c-Myc, in primary B-cells can induce apoptosis, and additional 
genetic elements are required for their cellular transformation [40]. To obtain Myc-driven 
lymphoma-like cell lines, we over-expressed c-Myc and inhibited the intrinsic and p53 
apoptosis pathways, respectively by retroviral transduction of c-Myc, BCLXL and BMI1 
expressing constructs. The transduced cells were pre-dominantly B-cells because they 
expressed CD19 and CD45R receptors but not the CD3 T-cell marker. 
Unlike previous studies, in our lymphoma-like cell system we progressively increased Myc 
expression levels by addition of increasing doxycycline levels in the culture medium and 
growing cells for 48 hours, which was followed by different experiments including flow 
cytometry and RNA sequencing. To simplify our analysis steps, we first compared 7 different 
doxycycline dose dependent expression levels of Myc in each cell system (WTMyc, 
T58AMyc or T58IMyc), and next we compared the data between WTMyc vs mutants or 
T58A vs T58I, respectively. 
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We first looked at Myc’s role in cell cycle progression, by analyzing cell cycle characteristics 
in response to the progressive increased Myc levels in all cell systems. Our result indicates 
that cell cycle phenotype of WTMyc and BL-AM (T58AMyc and T58IMyc) has a 
progressive increase in the proportion of cells in S-phase as Myc expression levels increase (0 
to 1000 µg/ml). Moreover, cell populations representing the G2/M phase, exhibit lower 
changes in response to increased Myc levels. However, T58AMyc and T58IMyc expressing 
cells have a lower proportion of cells in G2M compared to cells expressing WTMyc. 
To understand Myc and the phenotypic changes induced by its progressively increased 
expression during development of the lymphoma phenotype, as well as how these changes 
are augmented by adaptive BL mutations, we used inducible lymphoma-like cell systems to 
study their global gene expression by RNA sequencing. We first normalized count data, by 
adjusting to library size and gene length to produce TPM (Transcript Per Million) values. In 
order to choose the statistical methods and analyze our 3 dimensional data matrix (transcript 
counts vs Myc levels vs cell-lines), we first considered that the RNA sequencing count data 
had a skewed distribution. Second, we have multifactorial conditions in our data matrix. As 
previously described by other groups, the analytical approaches for multifactorial RNA-Seq 
data sets are sensitive to the normalization and statistical approaches, where as they report 
generalized linear models using non-binominal distribution are more accurate to detect 
differentially expressed genes (DEG) in multifactorial RNA-seq read count datasets [164, 
165]. Using generalized linear models we identified 4443 DEGs commonly changed in 
response to the progressive increase of the Myc levels in WTMyc cells as well as BL-AM. 
Moreover, we identified 543 DEG, which were deregulated only in BL-AM, suggesting that 
BL-Associated Mutations can deregulate a different subset of the Myc target genes in 
lymphoma-like systems. Interestingly, we found two DEG subsets that were commonly 
expressed in wild type and either of the mutants; WT&T58A (n=553) and WT&T58I 
(n=1062). However, we need to perform further analyses to find their biological roles. 
So far, we chose 6067 DEG in WTMyc expressing cells to visualize Myc transcriptional 
activities in WTMyc as well as BL-AM cell systems. Using the MaSigPro package in R we 
obtained 15 DEG model profiles, which mostly represent the different regulatory patterns 
regarding up and down regulated genes for all three Myc cell systems. Cells expressing T58I 
Myc proteins show the highest transcriptional levels in clusters 4, 8, 10 and12 compared to 
WTMyc and T58AMyc cell systems. In contrast, cells that expressed T58A Myc proteins 
show the lowest values for down-regulated genes in cluster 13, where as in cluster 15, cells 
expressing T58A have higher expression values compared to the other cells. 
Subsequently, we looked at the biological function of DEG in each defined cluster, by testing 
for enrichment of Gene Ontology (GO terms) using ClusterProfiler package (v3.6) in R. 
Interestingly, biological activity related to the ribosome biogenesis was enriched in cluster 9 
and 11, and in cluster 9 both of the BL-AM and in cluster 11, the T58AMyc mutant exhibited 
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higher transcriptional levels compare to the WTMyc cell line. Moreover, in cluster profiles 
10, 12 and 13 T58IMyc expressing cells, exhibited lower down regulation for the DEG 
associated with negative regulation of NF-KppaB activity, autophagy, cell adhesion, cell 
assembly, T-cell proliferation, histone and chromatin modifications, respectively, compared 
to the WTMyc and T58AMyc expressing cells. 
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8 DISCUTION AND FUTURE PERSPECTIVES 
Paper I: Phylogenetic and molecular evolution studies of Myc family proteins 
Transcription Factors (TF) are highly disordered proteins, proteome wide analysis revealed 
that from 94 to 82 % of TFs have extended intrinsic disorder regions (IDR), which include 
many transcriptional activation domains [77]. This characteristic appears to be important for 
different functional roles, including interaction with and recruitment of different structurally 
unrelated partner proteins [75]. 
Intrinsic disorder prediction algorithms can reliably predict the propensity of the protein to be 
disordered for each amino acid residue along the length of a protein. By analogy and partial 
similarity to structured protein situations, it could be concluded that disordered pattern might 
be conserved in Myc family proteins, although the amino acid sequences are highly 
divergent. Thus, evolutionary conservation of the IDR patterns could be a useful tool for the 
phylogenetic classification of Myc proteins in mammals. In particular, we compared different 
dendograms using disorder data predicted by different algorithms, which showed positive 
correlations for all dendograms as well as some clear differences between different IDR 
predictor algorithms. Importantly, protein disorder prediction should be regarded as a 
complementary approach beside sequence based methods, for measuring Myc family protein 
relationships, and this IDR based method should not be considered as a replacement for DNA 
and protein approaches.  
Moreover, furthered studies will be necessary in order to understand different parameters that 
influence the use of intrinsic disorder data and their relationship to identifying characteristics 
of proteins. In particular it will be of interest to analyze the evolution of different 
transcription factors as well as other proteins using both sequence based and the intrinsic 
disorder profiling methods. Indeed, additional approaches implemented using IUPred [166, 
167](ANCHOR) and PONDR®VLXT [156, 168] (alpha-MoRF) can identify short ordered 
regions within the disorder region, as possible binding domains in the disordered regions. 
Comparing this data beside sequence based conserved domains of TFs could be informative 
for understanding rapid evolution of TFs and the functional characteristics of their conserved 
binding domains.   
Alternatively, adaptive mutations might change biological functionality of a protein by 
changing the disorder profile of the disordered proteins, and therefore may influence the 
protein propensity for interacting with other partner proteins. In the BL-associated mutation 
context, it is interesting to report that functionally relevant c-Myc mutations can differentially 
change the local intrinsic disorder of the c-Myc protein. 
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Paper II: Functional analysis of Myc family proteins in mammalian cells 
Yeast studies revealed that genes transcribed by RNA polymerase II form loop structures at 
the juxtaposition of the upstream and downstream regions of genes [169]. Thus, this spatial 
architecture of genes is thought to put the transcribing RNA polymerase in close proximity to 
promoter regions in order to facilitate re-initiation of transcription upon termination of a 
previous transcript [170], thus making a more efficient transcription hub for rDNAs. 
Previously, our group suggested a model in which c-Myc can bind to the rDNA and induce 
such gene looping in growing cells[121]. 
In paper II, we characterized and report a new role of c-Myc in rDNA transcription of 
mammalian cells. Firstly, we studied the nucleolus compartment and showed the role of c-
Myc in rDNA transcription and its role of mediating nuclear matrix/scaffold attachment of 
rDNA. This role of the c-Myc protein in the nucleolus has not been reported before nor have 
similar roles of c-Myc been described in non-nucleolar contexts. Using Chip-3C assay we 
revealed that c-Myc can physically mediate rDNA attachment to the matrix, coupling with 
the MAR-methylation assay, which implies these matrix-attached rRNA genes are Hypo-
methylated in the upstream core promoter and thereby more accessible for transcription.  
Further investigation is needed to determine how Myc interaction with its co-factors and 
other nucleolar proteins, including UBF and SL1 can mediate this spatial organization of the 
mammalian rDNA. 
Paper III: Lymphoma-associated gene expression changes in an inducible model of 
Myc-driven B-cell Lymphoma 
We have been interested to understand Myc’s roles in lymphoma development and how 
Burkitt’s lymphoma associated mutations affect the Myc protein and augment Myc’s roles. 
The most prominent recent in vitro studies to date have used inducible Myc expression in the 
P493-6 (B-cell) and U2OS (osteosarcoma) cell lines [171, 172]. In addition, fibroblast cell 
lines have frequently been used for detailed analysis of the role played by wild type Myc 
[172] and Burkitt Lymphoma Myc mutations [32]. Increase in ribosome biogenesis is a key 
factor for cancer cell growth and proliferation, during which new protein synthesis is critical 
for cancer cell proliferation. In this study, we found a significant enrichment of gene ontology 
terms for biological processes related to ribosome biogenesis, in differentially expressed gene 
clusters showing increased gene expression as the function of progressively increased 
expression of Myc. Our data is partially inconsistence with the studies of Myc in 
osteosarcomas suggesting that Myc can play different biological roles in different types of 
cancer cells. However, at the level of cell phenotype, our findings are consist with the other 
studies of Myc inducible systems, where Myc over-expression was associated with increased 
cell size and entry of cells into the S-phase of the cell cycle [37, 172]. To further understand 
and address how Burkitt’s lymphoma associated mutations contribution to lymphoma 
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development we made lymphoma-like transduced cells for the MycT58A and MycT58I 
mutations as well as MycWT. In comparison, a previous study on Myc and BL mutations in 
rat fibroblast-derived cell lines [32], we have found that in both data sets WTMyc and 
Burkitt’s lymphoma associated mutations regulate a major subset of common genes, as well 
as different subsets with specific DEG for Burkitt’s lymphoma associated mutations. In our 
results, deregulation of this major common gene subset (4443 genes) suggests that the 
mutations affecting Myc protein do not affect all Myc target genes. In addition, we observed 
that each BL-AM regulates a subset of genes similar to WTMyc but distinct from the other 
BL-AM. This contrasts with the rat fibroblast study that showed that BL-AM (T58I and 
E39D) had a very similar set of target genes, which is distinct from the target genes of wild 
type Myc. We need to in the future analyze the T58A (553) and T58I (1062) distinct subset of 
genes in order to find differences in their regulatory pathways.  
Moreover, we need to compare our GO data set with the previous works done in Myc driven 
cells. Since, mutant Myc has a different half-life compared to wild type and for different 
mutants we need to further relate our data set to the actual protein levels of WTMyc and BL-
AM in the studied cells.  
To further understand the influence of BL mutations, which change the intrinsic disorder 
profile of the Myc protein we need to study their effect on the propensity of Myc to interact 
with and recruit partner proteins. We need to explore on the proteome level and analyze Myc 
interacting partners by different methods including Myc Immunoprecipitation and mass 
spectrometry. 
 However, major aspects of how Myc and BL-AM affect ribosome biogenesis remain 
unclear. By using transduced cells from this study and our previous knowledge of Myc’s role 
in MAR and rDNA loop induction, it will be interesting to determine, how Myc and other 
nucleolar proteins can affect rDNA transcription during lymphoma development during the 
active transcription stage via different structural and epigenetic mechanisms.  
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